Ingevity Q1 Earnings Up, Revenues Down Y/Y on Repositioning Actions

09.05.25 16:30 Uhr

Werte in diesem Artikel

Ingevity Corporation NGVT recorded a first-quarter 2025 profit of $20.5 million or 56 cents per share. This compared favorably with a loss of $56 million or a loss of $1.54 per share in the year-ago quarter.Excluding one-time items, adjusted earnings in the quarter were 99 cents per share, up from 47 cents a year ago.Revenues fell 16.5% year over year to $284 million in the quarter. This decline was due to lower sales in the Industrial Specialties product line and the Advanced Polymer Technologies segment.(Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)Ingevity Corporation Price, Consensus and EPS Surprise Ingevity Corporation price-consensus-eps-surprise-chart | Ingevity Corporation QuoteNGVT’s Segmental ReviewThe Performance Chemicals division generated revenues of $95 million in the reported quarter, down around 35.4% year over year. Road Technologies' product line sales of $44.3 million were down 3%. Industrial Specialties’ product line sales of $50.7 million fell 50%, owing to the impact of the segment's repositioning measures, which were aimed at exiting lower-margin end markets. Earnings before interest, taxes, depreciation and amortization (EBITDA) for the segment rose 97% to negative $0.3 million as a result of the successful implementation of the repositioning plans and cost savings, as well as lower raw material costs.Revenues in the Performance Materials unit rose around 1.2% year over year to $146.8 million. This upside was driven by volume growth in the Asia Pacific region and China. North America witnessed lower volumes. But the metric improved due to a mix of more fuel-efficient vehicles. Segment EBITDA was $79.1 million, up 1.4%.Sales in the Advanced Polymer Technologies segment were down 12.1% to $42.2 million. This downside was due to higher volumes in the EMEA region and North America being offset by lower volumes in Asia. Segment EBITDA was $12.5 million, up 31.6%, due to higher utilization rates in preparation for a planned extended outage in the second quarter.NGVT’s FinancialsThe first-quarter operating cash flow was $25.4 million, with free cash flow of $15.4 million. There were no share repurchases during the quarter, leaving $353.4 million remaining under the current $500 million authorization. Net leverage improved to 3.3x from the previous quarter’s 3.6x.NGVT’s 2025 Outlook RevisedNGVT's focus will be on improving profitability and reducing leverage. With the current state of trade affairs in mind, NGVT has broadened the range of its guidance to incorporate the potential risks of lower expected global auto production. Per the revised guidance, sales are expected to be between $1.25 billion and $1.40 billion, and adjusted EBITDA between $380 million and $415 million.NGVT Stock’s Price PerformanceShares of Ingevity have lost 26.1% in a year compared with the industry’s 3.1% decline.Image Source: Zacks Investment ResearchNGVT’s Rank & Key PicksNGVT currently has a Zacks Rank #4 (Sell).Some better-ranked stocks in the Basic Materials space are Brenntag SE BNTGY, Contango Ore, Inc. CTGO and Avino Silver & Gold Mines Ltd. ASM. While BNTGY and CTGO sport a Zacks Rank #1 (Strong Buy) each, ASM carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.BNTGY is slated to report first-quarter results on May 14. The Zacks Consensus Estimate for Brenntag’sfirst-quarter earnings is pegged at 24 cents per share.Contango is scheduled to report first-quarter results on May 14. The Zacks Consensus Estimate for CTGO’s first-quarter earnings is pegged at a loss of 32 cents per share. CTGO’s earnings beat the Zacks Consensus Estimate in three of the trailing four quarters while missing in one, with the average surprise being 213.7%.Avino Silver & Gold Mines is slated to release first-quarter results on May 13. The consensus estimate for ASM’s first-quarter earnings is pegged at 3 cents per share. ASM delivered a trailing four-quarter earnings surprise of 94.4%, on average.  Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Avino Silver (ASM): Free Stock Analysis Report Ingevity Corporation (NGVT): Free Stock Analysis Report Brenntag AG (BNTGY): Free Stock Analysis Report Contango ORE, Inc. (CTGO): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Ingevity und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Ingevity

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Ingevity

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Ingevity Corp When Issued

Wer­bung

Analysen zu Ingevity Corp When Issued

DatumRatingAnalyst
18.07.2019Ingevity OutperformBMO Capital Markets
11.12.2018Ingevity HoldStifel, Nicolaus & Co., Inc.
10.06.2016Ingevity BuyBB&T Capital Markets
DatumRatingAnalyst
18.07.2019Ingevity OutperformBMO Capital Markets
11.12.2018Ingevity HoldStifel, Nicolaus & Co., Inc.
10.06.2016Ingevity BuyBB&T Capital Markets
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Ingevity Corp When Issued nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen